<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32934823</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2059-9781</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><PubDate><Year>2020</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of systems and integrative neuroscience</Title><ISOAbbreviation>J Syst Integr Neurosci</ISOAbbreviation></Journal><ArticleTitle>Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.15761/JSIN.1000229</ELocationID><Abstract><AbstractText>A recent analysis from Stanford University suggested that without any changes in currently available treatment, prevention, and public health approaches, we should expect to have 510,000 deaths from prescription opioids and street heroin from 2016 to 2025 in the US. In a recent review, Mayo Clinic Proceedings (October 2019), Gold and colleagues at Mayo Clinic reviewed the available medications used in opioid use disorders and concluded that in private and community practice adherence is more important as a limiting factor to retention, relapse, and repeat overdose. It is agreed that the primary utilization of known opioid agonists like methadone, buprenorphine and naloxone combinations, while useful as a way of reducing societal harm, is limited by 50% of more discontinuing treatment within 6 months, their diversion, and addiction liability. Opioid agonists may have other unintended consequences, like continuing the down regulation of dopamine systems. While naltrexone would be expected to have opposite effects, adherence is also low even after detoxification and long acting naltrexone injections. Recent studies have shown Naltrexone is beneficial by attenuation of craving via "psychological extinction" and reducing relapse. Buprenorphine is the MAT of choice currently but injectable Naltrexone plus an agent to improve dopaminergic function and tone may renew interest amongst addiction physicians and patients. Understanding this dilemma there is increasing movement to opt for the non-addicting narcotic antagonist Naltrexone. Even with extended injectable option there is still poor compliance. As such, we describe an open label investigation in humans showing improvement of naltrexone compliance and outcomes with dopamine augmentation with the pro- dopamine regulator KB220 (262 days) compared to naltrexone alone (37days). This well studied complex consists of amino-acid neurotransmitter precursors and enkephalinase inhibitor therapy compared to treatment as usual. Consideration of this novel paradigm shift may assist in not only addressing the current opioid epidemic but the broader question of reward deficiency in general.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Western University Health Sciences, Graduate College, Pomona, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lott</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Behavioral Precision Management, Geneus Health, LLC, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baron</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Western University Health Sciences, Graduate College, Pomona, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California San Francisco School of Medicine, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badgaiyan</LastName><ForeName>Rajendra D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine Mt Sinai, New York, NY, USA and Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital, San Antonio, TX, Long School of Medicine, University of Texas Medical Center, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, Mo, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 CX000479</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073884</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH073624</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R41 MD012318</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Syst Integr Neurosci</MedlineTA><NlmUniqueID>101671495</NlmUniqueID><ISSNLinking>2059-9781</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">agonist vs antagonist therapy</Keyword><Keyword MajorTopicYN="N">combination therapy of naltrexone and kb220</Keyword><Keyword MajorTopicYN="N">kb220</Keyword><Keyword MajorTopicYN="N">naltrexone</Keyword><Keyword MajorTopicYN="N">opioid crisis</Keyword><Keyword MajorTopicYN="N">pro-dopamine regulation</Keyword><Keyword MajorTopicYN="N">vivitrol&#xae;</Keyword></KeywordList><CoiStatement>Conflicts of interest Kenneth Blum, PhD through his companies and patents related to KB220 has licensed a number of companies to utilize this complex =pro-dopamine regulator</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>16</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32934823</ArticleId><ArticleId IdType="mid">NIHMS1618521</ArticleId><ArticleId IdType="pmc">PMC7489288</ArticleId><ArticleId IdType="doi">10.15761/JSIN.1000229</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pitt AL (2018) Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health: e1&#x2013;e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137764</ArticleId><ArticleId IdType="pubmed">30138057</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava AB (2018) Beyond supply: How we must tackle the opioid epidemic. Mayo Clin Proc 93: 269&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">29502558</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AR (2018) Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat 91: 57&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039975</ArticleId><ArticleId IdType="pubmed">29910015</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum K (2018) Genetic addiction risk score (GARS)&#x2122;, a predictor of vulnerability to opioid dependence. Front Biosci (Elite Ed) 10: 175&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">28930612</ArticleId></ArticleIdList></Reference><Reference><Citation>Dole VP (1966) Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med 66: 2011&#x2013;2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">5220498</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold MS (1987) Wonder drugs. New York, NY: Simon &amp; Schuster.</Citation></Reference><Reference><Citation>Center for Substance Abuse Treatment. Chapter 4-Oral Naltrexone. In: Incorporating Alcohol Pharmacotherapies into Medical Practice. 2009. U.S.: Substance Abuse and Mental Health Services Administration (US).</Citation><ArticleIdList><ArticleId IdType="pubmed">22514855</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberg H (1973) Naloxone, naltrexone, and related noroxymorphones. Adv Biochem Psychopharmacol 8: 33&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">4794989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleber HD (1987) Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 13: 1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">3687878</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold MS (1980) Anti-endorphin effects of methadone. Lancet 2: 972&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">6107608</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein A 1975. On the role of chemotherapy in the treatment of heroin addiction. Am J Drug Alcohol Abuse 2: 279&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">1227291</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis DC (1975) The clinical usefulness of narcotic antagonists: preliminary findings on the use of naltrexone. Am J Drug Alcohol Abuse 2: 403&#x2013;415</Citation><ArticleIdList><ArticleId IdType="pubmed">1227300</ArticleId></ArticleIdList></Reference><Reference><Citation>Schecter A (1975) Clinical use of naltrexone (EN 1639 A). Part II: experience with the first 50 patients in a New York City treatment clinic. Am J Drug Alcohol Abuse 2: 433&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">1227301</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien CP (1975) Clinical experience with naltrexone. Am J Drug Alcohol Abuse 2: 365&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">1227298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurzeler MD (1976) Varying clinical contexts for administering naltrexone. NIDA Res Monogr 9: 48&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">794721</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli JR (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">1345133</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum K (1975) Effects of naloxone on ethanol withdrawal: Preference and narcosis. Pharmacologist 17(197).</Citation></Reference><Reference><Citation>Blum K (1977) Naloxone induced inhibition of ethanol dependence in mice. Nature 265: 49&#x2013;51, January 6.</Citation><ArticleIdList><ArticleId IdType="pubmed">556802</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald RD (2016) Extended-release naltrexone opioid treatment at jail reentry (XOR). Contemp Clin Trials 49: 57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5455014</ArticleId><ArticleId IdType="pubmed">27178765</ArticleId></ArticleIdList></Reference><Reference><Citation>Swift R (2011) Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs 72: 1012&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9798465</ArticleId><ArticleId IdType="pubmed">22051215</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AR (2017) Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders. Am J Addict 26: 319&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5426981</ArticleId><ArticleId IdType="pubmed">28328148</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TJ (2004) Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. Med Hypotheses 63: 538&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">15288384</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum K (2018) Pro-Dopamine Regulator (KB220) A fifty year sojourn to combat reward deficiency syndrome (RDS): Evidence based bibliography (Annotated). CPQ Neurol Psychol 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448775</ArticleId><ArticleId IdType="pubmed">30957097</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkes H (2000) Reduction of alcohol drinking and upregulation of opioid receptors by oral naltrexone in AA rats. Alcohol 21: 215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">11091024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchmayer U (2001) Naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 2: CD001333.</Citation><ArticleIdList><ArticleId IdType="pubmed">11687108</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaram-Lindstr&#xf6;m N (2017) Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study. Transl Psychiatry 7: e1104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5416714</ArticleId><ArticleId IdType="pubmed">28440810</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum K (2015) rsfMRI effects of KB220Z&#x2122; on neural pathways in reward circuitry of abstinent genotyped heroin addicts. Postgrad Med 127: 232&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979602</ArticleId><ArticleId IdType="pubmed">25526228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kun&#xf8;e N (2014) Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. Br J Clin Pharmacol 77: 264&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4014017</ArticleId><ArticleId IdType="pubmed">23088328</ArticleId></ArticleIdList></Reference><Reference><Citation>Luciana M (2018) Adolescent neurocognitive development and impacts of substance use: Overview of the adolescent brain cognitive development (ABCD) baseline neurocognition battery. Dev Cogn Neurosci 32: 67&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039970</ArticleId><ArticleId IdType="pubmed">29525452</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum K (2019) Opioid substitution therapy: Achieving harm reduction while searching for a prophylactic solution. Current Pharmaceutical Biotechnology 20: 180.</Citation><ArticleIdList><ArticleId IdType="pubmed">31146660</ArticleId></ArticleIdList></Reference><Reference><Citation>Makani R (2017) Role of repetitive transcranial magnetic stimulation (rTMS) in treatment of addiction and related disorders: A systematic review. Curr Drug Abuse Rev 10: 31&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">29189190</ArticleId></ArticleIdList></Reference><Reference><Citation>Robison LS (2018) Exercise reduces dopamine D1R and increases D2R in rats: Implications for addiction. Med Sci Sports Exerc 50: 1596&#x2013;1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">29613999</ArticleId></ArticleIdList></Reference><Reference><Citation>Pin JP (2007) Allosteric modulators of GABA(B) receptors: mechanism of action and therapeutic perspective. Curr Neuropharmacol 5: 195&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656813</ArticleId><ArticleId IdType="pubmed">19305802</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum K (2018) Analysis of evidence for the combination of pro-dopamine regulator (KB220PAM) and naltrexone to prevent opioid use disorder relapse. EC Psychol Psychiatr 7: 564&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6226033</ArticleId><ArticleId IdType="pubmed">30417173</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava AB (2018) Naltrexone: A history and future directions. Cerebrum 1: 13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6353110</ArticleId><ArticleId IdType="pubmed">30746025</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z (2018) Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder. J Psychiatry Neurosci 43: 254&#x2013;261</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6019353</ArticleId><ArticleId IdType="pubmed">29947607</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanum L (2017) Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical non inferiority trial. JAMA Psychiatry 74: 1197&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583381</ArticleId><ArticleId IdType="pubmed">29049469</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD (2018) Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): multicenter, open-label, randomized controlled trial. Lancet 91: 309&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806119</ArticleId><ArticleId IdType="pubmed">29150198</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan M (2017) Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. Am J Psychiatry 174: 459&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5411308</ArticleId><ArticleId IdType="pubmed">28068780</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JJ (2018) The more things change: Buprenorphine/ naloxone diversion continues while treatment remains inaccessible. J Addict Med 12: 459&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214787</ArticleId><ArticleId IdType="pubmed">30095563</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurd YL (2018) Molecular genetics and new medication strategies for opioid addiction. Am J Psychiatry 175: 935&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6167195</ArticleId><ArticleId IdType="pubmed">30068261</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z (2019) Behavioral and accumbal responses during an affective go/no-go task predict adherence to injectable naltrexone treatment in opioid use disorder. Int J Neuropsychopharmacol M 22: 180&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6403086</ArticleId><ArticleId IdType="pubmed">30690502</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlo LJ (2011) Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice. J Addict Med 5: 279&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3223377</ArticleId><ArticleId IdType="pubmed">22107877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray LA (2018) Pharmacogenetic effects of naltrexone in individuals of east asian descent: Human laboratory findings from a randomized trial. Alcohol Clin Exp Res 42: 613&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086578</ArticleId><ArticleId IdType="pubmed">29265379</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan MA (2019) A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry 1: 129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358483</ArticleId><ArticleId IdType="pubmed">30336703</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum K (2016) Hypothesizing that a pro-dopaminergic regulator (KB220z&#x2122; Liquid Variant) can induce &#x201c;dopamine homeostasis&#x201d; and provide adjunctive detoxification benefits in opiate/opioid dependence. Clin Med Rev Case Rep 3: 125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5638455</ArticleId><ArticleId IdType="pubmed">29034323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>